Cancer is a disease that fills patients with fear and uncertainty, regardless of the cancer type and the stage of the disease. The diagnosis can profoundly change the lives of both patients and their families. In the midst of these emotional challenges, however, a cancer blood test offers hope: The vast range of RGCC tests has the potential to improve the early detection of cancer and thus increases the chances of successful treatment.
Through tailored tests, RGCC aims to empower people facing cancer with tailored insights that can change the course of their journey. The aim of the cancer blood tests is to detect, analyze and examine cancer cells early at every stage of the disease. The minimally invasive liquid biopsy test offer promising opportunities for early cancer detection and treatment. In this process, the focus is always on providing patients with a clinical basis on which they can make a well-founded and personalized decision for individual cancer treatment.
The liquid biopsies represent a transformative approach to cancer testing and research, offering distinct advantages over traditional tissue biopsies. Minimally invasive and more convenient, liquid biopsies involve a simple blood draw, making them patient-friendly. Moreover, they are cost-effective, enhancing accessibility for patients and healthcare practitioners alike.
Additionally, unlike traditional biopsies that offer insights from one specific location in the body, liquid biopsies capture information from distant (metastatic) sites as well. This means that liquid biopsies paint a complete picture of cancer throughout the patient’s body, offering a comprehensive perspective that can be invaluable for precise diagnosis and treatment planning.
Onco-D-Clare is a cancer screening test designed to identify cancer even before the symptom’s onset. With the ease of a simple blood draw, you can now detect cancer long before any symptoms emerge. Onco-D-clare opens an early door to personalized health insights.
Onconomics Plus offers a comprehensive solution for selecting personalized treatment plans. This test evaluates the chemosensitivity of both conventional drugs and natural substances, determining the effectiveness of various chemotherapeutic agents. Additionally, it assesses tumor cell sensitivity to natural extracts, identifying which supplements are beneficial. The test also provides insights into the effectiveness of hyperthermia and radiation treatments on cancer, integrating this information with genetic data for a holistic approach to therapy selection
